Bio-Techne Corporation filings document the formal disclosure record for a Minnesota life sciences company that sells reagents, analytical instruments and precision diagnostics. Recent Form 8-K reports furnish quarterly and annual operating results, financial condition updates and cash dividend announcements, with exhibits containing the related earnings and dividend releases.
Governance filings include definitive proxy materials and annual meeting vote results covering board size and director elections. Other current reports disclose executive leadership changes and employment arrangements for segment management, tying corporate governance disclosures to Bio-Techne's diagnostics, spatial biology and analytical solutions operations.
TECH reported proposed secondary sales under Form 144 tied to option exercises. The filing lists multiple planned sales dated 05/08/2026 — including 2,212 shares and 4,424 shares from exercises under a registered plan, and a prior sale by Joshua Molho of 1,976 shares on 02/17/2026 for $116,791.48. The entries state the sales arise from exercises under a registered plan and identify the issuer as the seller in those lines.
BIO-TECHNE Corp CFO James Hippel reported compensation-related equity activity. On May 5, 2026, he exercised 62,000 shares of stock options into common stock at an exercise price of $47.60 per share, converting a derivative award into direct share ownership.
On the same date, 56,955 shares of common stock were disposed of in a tax-withholding transaction at $56.68 per share, covering exercise price or tax obligations rather than representing an open-market sale. Following the exercise, his direct common stock holdings were 210,625 shares, and after tax withholding they were 153,670 shares, while he retained a substantial portfolio of unexercised options and restricted stock units.
BIO-TECHNE Corp senior vice president and general counsel Shane Bohnen reported routine equity compensation activity. On May 5, 2026, he exercised stock options to acquire 8,400 shares of common stock at an exercise price of $47.60 per share.
On the same date, 7,055 shares of common stock were disposed of at $56.68 per share to satisfy tax obligations, a tax-withholding disposition rather than an open-market sale. Following these transactions, Bohnen directly owned 14,304 shares of BIO-TECHNE common stock, and continued to hold a substantial package of unexercised options and restricted stock units that vest over several future dates.
Bio-Techne Corp Chief Executive Officer Kim Kelderman reported routine equity compensation activity. On the reported date, he exercised stock options to acquire 26,692 shares of common stock at $47.60 per share, while 23,951 shares of common stock were withheld to cover tax obligations. After these transactions, he directly owned 89,750 common shares, and retained a substantial position in stock options and restricted stock units that remain outstanding.
Bio-Techne Corporation reported net sales of $311.4 million for the quarter ended March 31, 2026, down 2% from a year earlier, as softer Protein Sciences demand outweighed growth in Diagnostics and Spatial Biology. Organic revenue declined 2%, with foreign currency adding 2% and the absence of a held-for-sale business subtracting 2%.
Despite lower sales, GAAP net earnings rose to $51.0 million from $22.6 million, helped by a sharp reduction in litigation charges and ongoing cost management. Diluted EPS was $0.32, up from $0.14. Reported gross margin was 66.9%, slightly below last year as product mix shifted, and adjusted gross margin was 70.4%.
Operating cash flow for the nine months reached $196.7 million, up from $189.4 million, supporting higher cash and cash equivalents of $209.8 million and enabling $146.0 million of debt repayment, reducing long-term debt to $200.0 million. Segment operating margins remained strong at 44.2% for Protein Sciences and improved to 12.1% for Diagnostics and Spatial Biology, reflecting restructuring benefits and the Exosome Diagnostics divestiture.
Bio-Techne Corporation reported net sales of $311.4 million for the quarter ended March 31, 2026, down 2% from a year earlier, as softer Protein Sciences demand outweighed growth in Diagnostics and Spatial Biology. Organic revenue declined 2%, with foreign currency adding 2% and the absence of a held-for-sale business subtracting 2%.
Despite lower sales, GAAP net earnings rose to $51.0 million from $22.6 million, helped by a sharp reduction in litigation charges and ongoing cost management. Diluted EPS was $0.32, up from $0.14. Reported gross margin was 66.9%, slightly below last year as product mix shifted, and adjusted gross margin was 70.4%.
Operating cash flow for the nine months reached $196.7 million, up from $189.4 million, supporting higher cash and cash equivalents of $209.8 million and enabling $146.0 million of debt repayment, reducing long-term debt to $200.0 million. Segment operating margins remained strong at 44.2% for Protein Sciences and improved to 12.1% for Diagnostics and Spatial Biology, reflecting restructuring benefits and the Exosome Diagnostics divestiture.
FMR LLC reports beneficial ownership of 7,859,928.33 shares of BIO-TECHNE CORP common stock, representing 5.0% of the class as of 03/31/2026. The filing states FMR LLC has sole dispositive power for 7,859,928.33 shares and discloses related signatures and a Power of Attorney reference.
FMR LLC reports beneficial ownership of 7,859,928.33 shares of BIO-TECHNE CORP common stock, representing 5.0% of the class as of 03/31/2026. The filing states FMR LLC has sole dispositive power for 7,859,928.33 shares and discloses related signatures and a Power of Attorney reference.
Bio-Techne Corporation reported mixed third quarter fiscal 2026 results. Net sales were $311.4 million, down 2% year over year, with organic revenue also declining 2% as prior-year GMP fast-track orders and timing of large Commercial Supply shipments weighed on growth.
GAAP earnings improved sharply, with diluted EPS rising to $0.32 from $0.14, driven by a 95% increase in GAAP operating income to $75.5 million and a higher 24.2% operating margin helped by profitability initiatives and the Exosome Diagnostics divestiture. On a non-GAAP basis, adjusted EPS slipped to $0.53 from $0.56 and adjusted operating margin eased to 34.2% from 34.9%.
The Protein Sciences segment posted revenue of $226.2 million, down 1%, with organic revenue down 4%, while Diagnostics and Spatial Biology revenue declined 4% to $85.6 million but delivered 3% organic growth and margin expansion. The company ended the period with $209.8 million in cash and equivalents and reduced long-term debt to $200 million. The Board declared a quarterly cash dividend of $0.08 per share, payable May 29, 2026 to shareholders of record on May 18, 2026.
Bio-Techne Corporation reported mixed third quarter fiscal 2026 results. Net sales were $311.4 million, down 2% year over year, with organic revenue also declining 2% as prior-year GMP fast-track orders and timing of large Commercial Supply shipments weighed on growth.
GAAP earnings improved sharply, with diluted EPS rising to $0.32 from $0.14, driven by a 95% increase in GAAP operating income to $75.5 million and a higher 24.2% operating margin helped by profitability initiatives and the Exosome Diagnostics divestiture. On a non-GAAP basis, adjusted EPS slipped to $0.53 from $0.56 and adjusted operating margin eased to 34.2% from 34.9%.
The Protein Sciences segment posted revenue of $226.2 million, down 1%, with organic revenue down 4%, while Diagnostics and Spatial Biology revenue declined 4% to $85.6 million but delivered 3% organic growth and margin expansion. The company ended the period with $209.8 million in cash and equivalents and reduced long-term debt to $200 million. The Board declared a quarterly cash dividend of $0.08 per share, payable May 29, 2026 to shareholders of record on May 18, 2026.
Bio-Techne Corp executive Steven C. Crouse reported routine equity compensation activity involving company stock. On May 1, 2026, he exercised 794 Restricted Stock Units, which converted into an equal number of Bio-Techne common shares.
To cover tax obligations, 311 common shares were disposed of through a tax-withholding transaction, a non-market event that does not represent an open-market sale. Following these transactions, Crouse directly holds 6,688 shares of common stock, alongside multiple option and restricted stock unit awards that vest over several future dates.
Bio-Techne Corp reports that Vanguard Capital Management beneficially owns 11,559,571 shares of Common Stock, representing 7.38% of the class. The filing states Vanguard exercises sole dispositive power over 11,559,571 shares and sole voting power over 1,379,862 shares. The filing attributes ownership to Vanguard Capital Management and affiliated Vanguard entities per SEC Release No. 34-39538.
Bio-Techne Corp Chief Executive Officer Kim Kelderman reported compensation-related equity activity, not open-market trading. On April 22, 2026, Kelderman exercised stock options to acquire 11,344 shares of Bio-Techne common stock, while 1,363 shares were disposed of to cover tax obligations at $58.58 per share. This left Kelderman with 63,058 common shares held directly after these transactions.
The filing also lists substantial remaining equity incentives, including multiple tranches of stock options and restricted stock units tied to vesting schedules and performance goals, with option exercise prices ranging from $47.60 to $120.46 and expirations extending to August 15, 2035.